Phase 2 Atrial Fibrillation Trial, Recruiting NCT07217067 Sponsor: Novartis Pharmaceuticals Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 2 Atrial Fibrillation Trial, Recruiting

NCT07217067
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • You have had at least 2 episodes of atrial fibrillation (AF) or atrial flutter, and at least one of those must have been atrial fibrillation specifically
  • At least one of those AF episodes happened within the last 12 months and was recorded by a heart monitor or ECG machine, as confirmed by the trial doctor
  • You meet at least one of the following: your heart was in an irregular rhythm for 1% or more of the time on a wearable heart monitor within the last 12 months; you have a certain risk score for stroke based on conditions like heart failure, high blood pressure, diabetes, age, or past strokes (confirm with trial site for your specific score); you have mild or stable heart failure with few or no symptoms; or a specific heart-related protein in your blood (NT-proBNP) was measured at 300 pg/mL or higher within the last 12 months
  • You are currently taking stroke-prevention medication as recommended by your doctor
  • Your body weight relative to your height (BMI) is 18 or above
  • Your heart is in a normal rhythm at the start of the trial, confirmed by an ECG (if your heart is not in normal rhythm, it may need to be reset at least 12 hours before you officially join)

Who may not be able to join:

  • You have permanent atrial fibrillation (AF that does not go back to normal rhythm)
  • Your AF is being caused by a treatable or temporary condition, such as thyroid problems, heart inflammation, heavy alcohol use, an infection, recent surgery, or a blood clot in the lungs
  • You are currently taking certain heart rhythm medications (some must be stopped for at least 7 days before the trial, and one specific medication called amiodarone must be stopped at least 6 weeks before — confirm with trial site)
  • You previously had a procedure to correct your AF (called an ablation) and have not had any AF episodes in the 2 or more months since that procedure
  • You have a pacemaker, defibrillator, or implanted heart monitor
  • You have a specific type of heart muscle disease, such as amyloidosis, sarcoidosis, or hypertrophic cardiomyopathy (confirm with trial site)
  • Your heart's pumping strength (ejection fraction) was measured at 40% or below within the last 12 months
  • You are currently experiencing worsening heart failure or were hospitalised for heart failure within the last 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: 1-888-669-6682

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
28 October 2025
Est. completion
9 September 2027

Where this trial is recruiting

🇨🇦 Canada 🇨🇳 China 🇩🇪 Germany 🇳🇱 Netherlands 🇸🇬 Singapore 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Atrial fibrillation burden from ECG patch monitors

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov